A Phase 2 interventional study of aflibercept and oxaliplatin in Colorectal Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 14 in phase 2, and was the 2nd registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 268 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
24 studies in Colorectal Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 24 studies in Colorectal Neoplasms by Sanofi, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2009, is one of 7 in phase 2, and was the 12th registered.
Sanofi’s Colorectal Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 24 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
Secondary objectives include the evaluation of overall objective response rate to treatment, progression-free survival, overall survival, safety and documentation of potential immunogenicity of aflibercept.
This study was a non-comparative randomized trial and was not powered for a comparison of any of the efficacy endpoints.
Rather, the aim of the trial was to get, for all endpoints, an estimation of the efficacy and safety of aflibercept combined with a modified FOLFOX6 regimen. In such type of non-comparative randomized trial, the control FOLFOLX6 arm was intended to only act as a check on the similarity of the current patients to the historical controls with respect to clinical outcome when given FOLFOX6 treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
modified FOLFOX6 chemotherapy regimen
Drug: oxaliplatin · Drug: 5-FU · Drug: Folinic Acid
modified FOLFOX6 chemotherapy regimen in combination with aflibercept
Drug: aflibercept · Drug: oxaliplatin · Drug: 5-FU · Drug: Folinic Acid
administration: IV infusion
Also known as: ZALTRAP™, AVE0005
administration: IV infusion
administration: IV infusion
administration: IV infusion
Progression Free Survival (PFS) Rate at 12 Months
PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
Time frame: 12 months
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves. The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Overall Objective Response Rate (ORR)
Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population. Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study).
Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Overall Survival (OS)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date. The study was not powered for comparison of OS between the two arms (non-comparative, open-label study).
Time frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs.
Time frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
Immunogenicity of Intravenous (IV) Aflibercept
The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept.
Time frame: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status
| Milestone | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Started | 117 | 119 |
| Completed | 0 | 0 |
| Not completed | 117 | 119 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Adverse event | 26 | 36 |
| Withdrew: Disease progression | 52 | 47 |
| Withdrew: Poor compliance to protocol | 1 | 1 |
| Withdrew: Physician decision | 13 | 14 |
| Withdrew: Consent withdrawn | 0 | 2 |
| Withdrew: Withdrawal by subject | 11 | 12 |
| Withdrew: Metastatic surgery | 6 | 6 |
| Withdrew: Other | 7 | 1 |
PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
| percentage of participants | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Progression Free Survival (PFS) Rate at 12 Months | 21.2 (12.2 to 30.3) | 25.8 (17.2 to 34.4) |
PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves. The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
| Months | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Progression Free Survival (PFS) | 8.77 (7.622 to 9.265) | 8.48 (7.885 to 9.922) |
Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population. Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study).
| percentage of participants | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Overall Objective Response Rate (ORR) | 45.9 (36.4 to 55.7) | 49.1 (39.7 to 58.6) |
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date. The study was not powered for comparison of OS between the two arms (non-comparative, open-label study).
| months | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Overall Survival (OS) | 22.31 (15.57 to NA) | 19.45 (15.64 to NA) |
Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs.
| participants | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| Treatment Emergent Adverse Event (TEAE) | 115 | 119 |
| Grade 3-4 TEAE | 87 | 108 |
| Treatment emergent Serious Adverse Event (SAE) | 32 | 55 |
| TEAE leading to death | 2 | 8 |
| Premature treatment discontinuation | NA | 34 |
| Permanent treatment discontinuation | 26 | 37 |
The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept.
| participants | Negative or Missing | Positive |
|---|---|---|
| ADA Negative post-baseline | 105 | 1 |
| ADA Positive (drug specific) post-baseline | 7 | 2 |
| ADA Negative 90 days after last dose | 45 | 1 |
| ADA Positive 90 days after last dose | 0 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mFOLFOX6 Only | — | 32/116 (27.6%) | 114/116 (98.3%) |
| mFOLFOX6 + Aflibercept | — | 55/119 (46.2%) | 117/119 (98.3%) |
| Event | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| PyrexiaGeneral disorders | 3/116 | 6/119 |
| Intestinal obstructionGastrointestinal disorders | 4/116 | 2/119 |
| PneumoniaInfections and infestations | 1/116 | 4/119 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/116 | 4/119 |
| Disease progressionGeneral disorders | 1/116 | 4/119 |
| Catheter site infectionInfections and infestations | 3/116 | 3/119 |
| DiarrhoeaGastrointestinal disorders | 3/116 | 3/119 |
| Colonic obstructionGastrointestinal disorders | 3/116 | 0/119 |
| NeutropeniaBlood and lymphatic system disorders | 1/116 | 3/119 |
| Drug hypersensitivityImmune system disorders | 0/116 | 3/119 |
| Event | mFOLFOX6 Only | mFOLFOX6 + Aflibercept |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 51/116 | 69/119 |
| NeutropeniaBlood and lymphatic system disorders | 64/116 | 53/119 |
| HypertensionVascular disorders | 8/116 | 64/119 |
| NauseaGastrointestinal disorders | 62/116 | 62/119 |
| StomatitisGastrointestinal disorders | 44/116 | 60/119 |
| Decreased appetiteMetabolism and nutrition disorders | 37/116 | 41/119 |
| FatigueGeneral disorders | 30/116 | 41/119 |
| HeadacheNervous system disorders | 9/116 | 39/119 |
| ConstipationGastrointestinal disorders | 31/116 | 37/119 |
| Peripheral sensory neuropathyNervous system disorders | 35/116 | 23/119 |
| Age, Continuous(Years) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| Mean | 62.4 ± 9.7 | 61.8 ± 9.0 | 62.1 ± 9.4 |
| Age, Customized(Participants) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| <65 | 65 | 70 | 135 |
| >=65 but <75 | 43 | 45 | 88 |
| >=75 | 9 | 4 | 13 |
| Sex: Female, Male(Participants) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| Female | 49 | 43 | 92 |
| Male | 68 | 76 | 144 |
| Race/Ethnicity, Customized(Participants) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| Caucasian/White | 90 | 97 | 187 |
| Black | 0 | 1 | 1 |
| Asian/Oriental | 27 | 20 | 47 |
| Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| United Kingdom | 22 | 28 | 50 |
| Korea, Republic of | 26 | 20 | 46 |
| Germany | 18 | 24 | 42 |
| Spain | 24 | 18 | 42 |
| Russian Federation | 15 | 15 | 30 |
| Italy | 10 | 5 | 15 |
| Australia | 2 | 9 | 11 |
| Body Surface Are (BSA)(m^2) | mFOLFOX6 Only | mFOLFOX6 + Aflibercept | Total |
|---|---|---|---|
| Mean | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 |
The record gives a start of Feb 2009, a primary completion of Apr 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept